Your session is about to expire
← Back to Search
BEAM vs. Melphalan for Multiple Myeloma (BEAM Trial)
BEAM Trial Summary
This trial aims to compare the effectiveness of two different treatments for multiple myeloma. The first treatment is the standard of care, which is Melphalan. The second treatment is BEAM, which has not been well studied in multiple myeloma specifically, but has been studied in other lymphomas. Early data suggests that BEAM may be effective in multiple myeloma, but there is not enough data to know for sure. This trial will help to determine whether BEAM is more effective than Melphalan.
BEAM Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowBEAM Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From undefined Phase 3 trial • 1734 Patients • NCT00025259BEAM Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You do not have HIV.My kidneys are functioning well.I have had cancer before, but my life expectancy is less than 3 years due to it.I do not have any infections that aren't responding to treatment.I am scheduled for a specific bone marrow transplant procedure.I don't have enough stem cells stored for a transplant.I am willing to use contraception if needed during the study.Your bilirubin levels are less than 2 mg/dl, and your SGPT levels are less than 2.5 times the normal range.There is a specific type of protein in your blood called M-protein.I have undergone at least 2 treatment cycles for my multiple myeloma and have seen some improvement.I have had a stem cell transplant using my own cells.My health is severely impacted by a life-threatening condition.I have a history of seizures.I am mostly able to care for myself and carry out normal activities.My heart pumps well and I don't have serious heart rhythm problems.My myeloma has spread to my brain and is not under control.I am newly diagnosed with multiple myeloma and planning to undergo a stem cell transplant.My lung function is good and I don't have breathing problems.My tests show more than 10% cancer cells in my bone marrow or a confirmed cancerous tumor.You have dysfunction in your organs related to myeloma, such as high blood calcium, kidney problems, anemia, or bone issues.I have been diagnosed with amyloidosis.I am unable to understand or make decisions about my treatment.I am between 18 and 70 years old.You do not have a serious illness that could greatly shorten your life.
- Group 1: BEAM Regimen- Experimental Arm
- Group 2: Melphalan Regimen- Control Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are people currently being recruited for this experiment?
"Yes, as specified on clinicaltrials.gov, this trial is currently looking for volunteers. The listing was created on September 5th, 2018 and was edited most recently on June 21st, 2022. They are 100 individuals needed to complete the study at 1 location."
Has Cytarabine been cleared by the FDA for public consumption?
"While Phase 2 trials are not as reliable in terms of efficacy, the data collected thus suggest that Cytarabine is safe."
For what purpose is Cytarabine most commonly prescribed?
"Various forms of cancer, including small cell lung cancer (sclc), leukemia, myelocytic, acute, and neuroblastoma (nb) can all be treated with Cytarabine."
How many individuals are being recruited for this clinical research?
"Yes, the information on clinicaltrials.gov indicates that this trial is actively recruiting patients. The trial was first posted on September 5, 2018 and was most recently updated on June 21, 2022. The study is looking for 100 participants across 1 site."
Might I be eligible to participate in this clinical research?
"Eligibility for this study requires a cancer diagnosis of multiple myeloma and being between 18-70 years old. A total of 100 people are needed for the clinical trial."
Does this research include patients that are over 55 years old?
"This particular trial is only seeking patients aged 18-70. Out of the 772 total trials, 250 are for individuals below 18 years old and 1222 are for seniors above 65."
Share this study with friends
Copy Link
Messenger